ArticlePlastic and reconstructive surgery. Global open2026
Acellular Dermal Matrix-assisted Implant-based Breast Reconstruction: Surgical and Patient-reported Outcomes From the Mastectomy Reconstruction Outcomes Consortium Study.
Article in Plastic and reconstructive surgery. Global open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Acellular dermal matrices (ADMs) are used in most of the United States but are not FDA-approved for this indication. We evaluated SurgiMend (Integra) in immediate 2-stage subpectoral reconstruction versus no ADM. Methods: An FDA-aligned statistical analysis plan was applied to the prospective Mastectomy Reconstruction Outcomes Consortium cohort. Patients underwent 2-stage subpectoral implant-based breast reconstruction with SurgiMend or without ADM. BREAST-Q Physical Well-Being (Chest) scores were collected preoperatively and at 1 week, 3 months, 1 year, and 2 years. The primary outcome was composite clinical success, defined as a decline in BREAST-Q score of 4 point or less at 1 year and no major complication within 2 years. Results: Among 987 patients, 119 (12.1%) received SurgiMend and 868 (87.9%) underwent reconstruction without ADM. Mean age was 48.1±10.4 years. Mean body mass index was 25.8±5.3 kg/m Conclusions: SurgiMend was associated with fewer complications and higher patient-reported outcomes, supporting its safety and effectiveness in postmastectomy reconstruction.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.